Fragment 176-191
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
A narrow cutting adjunct for mobilizing fat during fasted training, not a standalone weight-loss drug.
The medical safety signal is low relative to full GH, but the efficacy risk is high: if dosing is not fasted, pre-activity, and paired with a deficit, the likely outcome is wasted spend rather than reliable fat loss.
A narrow cutting adjunct for mobilizing fat during fasted training, not a standalone weight-loss drug. The useful lane is a short active window before fasted cardio or fasted resistance work, where Fragment can amplify lipolysis without adding the IGF-1, water-retention, or glucose burden of full GH.
Health-risk signal is low for a GH-derived RUO peptide: the AOD-9604 clinical program did not show IGF-1 elevation, insulin resistance, glucose impairment, or classic GH water-retention effects. Practical risks are more common than medical risks: daytime lethargy or brain fog in some users, sleep/headache/nausea confusion when started with secretagogues, unverifiable RUO product quality, and wasted spend if the protocol is not fasted and activity-linked.
Fair only when the user can execute the protocol. At 500 mcg/day, typical RUO pricing puts it around $2–4/day; workout-days-only dosing can lower total cycle cost because rest-day injections are the lowest-value use. It becomes poor value on top of full exogenous GH, in caloric surplus, or for users who want appetite suppression rather than lipolytic timing support.
Bullish but bounded in the right setup: fasted, pre-activity, caloric deficit, and enough weeks of body-composition tracking to see a trend. Skeptical everywhere else. The failed obesity-drug program tested monotherapy weight loss in obese patients, while community use treats Fragment as a protocol-dependent lipolysis amplifier rather than a replacement for diet, training, or stronger pharmacologic fat-loss tools.
Intro
Fragment 176-191 is the 16-amino acid C-terminal segment of human growth hormone, corresponding to residues 176 through 191 of the full GH sequence.
Its core property is dissociation: this fragment retains the lipolytic activity of GH's C-terminal domain while having no affinity for the GH receptor, producing no IGF-1 stimulation, and carrying none of the anabolic or metabolic side effects of full exogenous GH. The compound reaches adipose tissue and activates fat mobilization through a pathway distinct from GH receptor signaling — essentially, the fat-burning portion of GH's mechanism, isolated and delivered without the rest.
The pharmaceutical history matters for context. AOD-9604 — the stabilized, tyrosine-modified form of the native fragment — progressed through six Phase 2b/3 randomized clinical trials for obesity treatment before the program was halted in 2007. The trials failed to demonstrate clinically meaningful weight loss in obese patients. The safety data from those trials, however, was consistently clean: no IGF-1 elevation, no insulin resistance, no glucose impairment, no mutagenic activity. Following the efficacy failure, AOD-9604 was reclassified as a nutraceutical ingredient. The compound did not disappear — it shifted into the research compound market, where both the native Fragment 176-191 and AOD-9604 continue to be used by the performance and bodybuilding community.
Community adoption predates the full clinical trial readout. By 2013, Fragment 176-191 had established recurring discussion across English-language and European bodybuilding communities. The positioning was consistent: a budget-accessible, targeted fat loss compound for cutting phases, used without the water retention and hormonal disruption of full HGH. Practitioners framing it most accurately describe Fragment as 'what GH does to fat, without what GH does to everything else.'
The compound's community reputation is defined by a persistent split. Some users report meaningful fat loss amplification; others report nothing. The split largely dissolves when protocol context is examined: positive reports consistently involve fasted pre-exercise timing in a caloric deficit; negative reports more often reflect use in surplus or without fasted training. The mechanism requires these conditions — Fragment amplifies a fat mobilization process that must already be occurring rather than creating it independently. The clinical trial failure in obese patients as monotherapy is not the same experiment as an experienced practitioner running Fragment before fasted cardio during a 12-week cut.
Since 2020, GLP-1 receptor agonists have moved to the center of community fat loss discussion. Semaglutide and tirzepatide produce stronger, more reliable fat loss than Fragment and are now more commonly the primary fat loss tool, with Fragment repositioned as an adjunct. Its current niche is in TRT and secretagogue-stacking protocols, where users want targeted lipolytic support without introducing IGF-1 elevation or glucose disruption.
Observed Effects
Primary: Fat mobilization enhancement The primary observed effect is increased lipolysis during fasted exercise.
Community practitioners who run Fragment in its intended context — fasted, pre-cardio, in a caloric deficit — consistently describe enhanced fat loss relative to baseline. No community reports with specific quantified outcomes (DEXA before/after, body weight change attributed to Fragment as an isolated variable) were identified; most positive reports are embedded in protocols with simultaneous dietary and training changes that confound attribution. The mechanism-consistent pattern is that Fragment accelerates fat mobilization from adipose tissue during the fasted exercise window, not that it produces fat loss at rest.
In AOD-9604 clinical trials, the early Phase 1/2 studies demonstrated positive fat metabolism activity sufficient to justify a drug development program. The Phase 2b/3 obesity trials failed to show the weight loss magnitude required for drug approval in a sedentary obese population. Animal models (Zucker rats, mice, rabbits) showed consistent body weight reduction across species, which drove the pharmaceutical program. Taken together: Fragment does something to fat metabolism in animal models and early human studies, but not enough to function as a monotherapy obesity drug in the clinical trial context.
Secondary: Absence of GH side effects The secondary effect profile is defined by what Fragment does not do. Six clinical RCTs confirmed: no significant IGF-1 elevation, no insulin resistance, no impaired glucose tolerance. Users do not experience the water retention, carpal tunnel syndrome, or hyperglycemia associated with exogenous GH. This absence is not a minor footnote — it defines Fragment's entire value proposition relative to full GH for users who want only the fat loss mechanism without the metabolic and anabolic downstream effects.
Lean mass preservation Some community members report lean mass preservation during cutting phases alongside fat loss, consistent with what would be expected from reducing catabolism of muscle during caloric restriction. No quantified data. This is plausible given the fat-as-fuel pathway but should not be stated as a confirmed outcome.
Field Reports
The most reliable pattern in community experience reports is that positive outcomes cluster tightly around a specific protocol context: fasted, pre-activity, in a caloric deficit, during a dedicated cutting phase.
Users who run Fragment this way describe it as an effective lipolytic amplifier. The strongest endorsements frame fasted cardio plus lipolytic support as clearly noticeable within the right conditions rather than as a subtle effect requiring bloodwork to detect.
What works Fasted pre-cardio timing is the single most consistent predictor of positive outcomes. Users who inject 30–60 minutes before fasted steady-state cardio and maintain a 3-hour post-injection fast report the clearest fat loss enhancement. The protocol specificity is not excessive — it maps directly to the mechanism. Multiple experienced practitioners have converged on 250 mcg AM fasted + 250 mcg PM fasted (pre-second workout or cardio session) as a cost-effective way to maintain two active windows per day given the short half-life.
Workout-days-only condensation is a widely practiced cost reduction strategy with no apparent loss of efficacy. Several practitioners report that skipping rest-day injections produces the same cutting-phase outcomes as daily dosing at meaningfully lower cost — consistent with the mechanism's exercise dependence.
Side effects in practice Daytime lethargy and brain fog are the most documented adverse experience. Multiple independent reports across English and Hungarian communities describe the same pattern: training feels good, but the rest of the day is characterized by fatigue and mental fog. One user's description compared the sensation to intoxication and was specific enough to match other community documentation. The side effect does not appear to be universal; many users report none. Whether it's a direct effect, a fat mobilization consequence, or an individual susceptibility is not established.
Simultaneous compound starts consistently produce unattributable side effects. Users who started Fragment and sermorelin in the same week — sermorelin specifically intended to improve sleep — reported worse sleep, morning headaches, and nausea. Causal attribution to Fragment requires isolated starts.
Common confounders First-person reports are nearly universally confounded. One detailed positive report paired Fragment with removing soda and refined sugar, so the body-composition change could not be isolated from the diet change. This pattern means almost no positive community report provides clean attribution. It does not mean Fragment doesn't work; it means Fragment's effect size relative to the other changes in the protocol is unknown from self-reports.
Common mistakes Running without fasted exercise removes the mechanism's activation requirement. Running in caloric surplus removes the lipolytic context. Stacking with full exogenous GH makes it redundant. Under-dosing due to cost (100–150 mcg instead of 250 mcg minimum) is documented in discussions where users try to stretch vials. Starting simultaneously with other compounds prevents attribution of either benefits or side effects.
Community Consensus
Fragment 176-191 has been discussed in bodybuilding and performance communities since at least 2013, including English-language, TRT/HRT, Dutch-language, and Hungarian-language circles.
It established early as the go-to dedicated fat-loss peptide for users targeting lipolysis without the broader GH axis — the compound community members reach for when they want GH's fat-burning mechanism without the anabolic package.
The community's verdict on Fragment is more split than most established peptides. Early discussion captured the defining tension: reviews were often either strongly dismissive or clearly positive, with little middle ground. Unlike BPC-157 or TB-500, which generate broadly positive consensus, Fragment divides practitioners. The split largely resolves when protocol context is examined — users reporting positive outcomes consistently describe fasted pre-exercise use in a caloric deficit; users reporting nothing more often describe use without those conditions, or in caloric surplus. The compound amplifies a process that must already be occurring; it does not independently create fat loss.
The TRT and HRT community has been a consistent base for Fragment use. These are typically men already managing testosterone replacement who want targeted fat loss support without adding IGF-1 elevation, water retention, or glucose complications. The clinical safety profile carries credibility in a population that monitors bloodwork and health parameters carefully. Fragment's profile fits this demographic more cleanly than most fat loss compounds.
Experienced performance practitioners position Fragment strictly as a cutting-phase adjunct, not a standalone. The consensus is that it belongs alongside fasted cardio in a deficit, and sometimes alongside GH secretagogues for broader GH-axis coverage. Adding Fragment to a protocol already containing full exogenous GH is treated as redundant and wasteful — the lipolytic domain is already present in the GH molecule. This 'redundant on full GH' insight is the most practically useful community finding: it defines exactly when Fragment is and is not worth adding.
Since roughly 2020, GLP-1 agonists (semaglutide, tirzepatide) have displaced Fragment as the primary community fat loss peptide. The GLP-1 class produces stronger and more reliable fat loss with less protocol specificity than Fragment requires — no fasted timing, no exercise dependency, meaningful results even without structured training. Fragment's current positioning is as a complementary lipolytic tool that layers onto GLP-1 or secretagogue protocols rather than as the lead compound it was in the 2013–2019 period.
AOD-9604 and Fragment 176-191 are treated as interchangeable by most community practitioners. Experienced members who have run both describe no clear night-and-day difference in practical fat loss outcome. Both are available from RUO channels; the choice is typically made on price and market availability rather than perceived pharmacological superiority. Fragment 176-191 and AOD-9604 are both WADA-prohibited as GH variants — relevant only for drug-tested competitive athletes.
Risks & Monitoring
Commonly reported: Lethargy and brain fog Daytime fatigue and cognitive dulling are the most consistently documented adverse effects from community reports.
Multiple independent reports across different forums and languages (English-language forums, a Hungarian bodybuilding community in 2016) describe the same pattern: users feel energized during training but experience persistent fatigue and mental fog throughout the rest of the day. One account described it as a feeling resembling intoxication. The side effect was prominent enough that the user sought out community discussion about it and found it already documented online. The mechanism is not established — it resembles GH-related tiredness despite Fragment not raising systemic GH. Secondary metabolic shifts from rapid fat mobilization are the most plausible explanation, but this has not been investigated.
Reported in combination protocols: Sleep disruption, headaches, nausea At least one user starting Fragment simultaneously with sermorelin — specifically to improve sleep — reported paradoxical sleep worsening, morning headaches, and nausea in the first week. Causal attribution to Fragment cannot be made when two compounds are started at the same time; sermorelin's GH pulse adaptation may account for the sleep disruption. The pattern is documented but the compound-specific attribution is unclear. If running Fragment alongside GH secretagogues, starting one compound at a time allows meaningful attribution of any early side effects.
Not reported / absent per clinical data Water retention, carpal tunnel syndrome, glucose dysregulation, and IGF-1 elevation are all absent across six clinical trials. This is Fragment's defining safety advantage over full exogenous GH for users who want only fat loss. No serious adverse events were reported in the AOD-9604 clinical program. No mutagenic potential was identified in the Ames test; no chromosomal aberration activity in CHO cell assay.
Practical note No blood test can confirm Fragment use or detect product quality issues — the compound produces no detectable IGF-1 or GH signal. Product authenticity from RUO channels is therefore unverifiable via standard bloodwork.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
The article's defining mechanistic claim — confirmed across six clinical RCTs — is that Fragment does NOT raise IGF-1. Baseline IGF-1 establishes the user's pre-cycle reference; a midcycle re-check confirming stable IGF-1 verifies the compound is behaving as expected (no GHR activation) and distinguishes Fragment from any inadvertent GH-axis contamination in the source product.
Confirms the expected null effect on IGF-1 per the article's practicalConsiderations 'biomarkers to track' subsection — 'not to measure Fragment specifically, but to confirm the expected profile (stable IGF-1, stable glucose) rather than a side effect.' Unexpected elevation suggests source quality problem (cross-contamination with GH or full-length analogs).
The article documents Fragment as having no glucose dysregulation across six clinical trials — explicitly absent vs full GH. Baseline plus midcycle confirmation is part of the 'expected null profile' verification per practicalConsiderations, and ensures any cutting-phase glucose changes are attributable to caloric deficit rather than the compound.
Mid-cycle confirmation. The article's practicalConsiderations 'biomarkers to track' frames glucose as a sanity check — stable glucose validates the clinical safety profile in the user's specific context.
Companion to fasting glucose for HOMA-IR. The article documents Fragment does not cause insulin resistance — baseline insulin establishes the user's pre-cycle metabolic state for distinguishing protocol-driven changes (fasted training, deficit) from any rare individual response.
Pre-cycle metabolic baseline appropriate for the cutting-phase context where Fragment is deployed. The article positions Fragment alongside fasted cardio in a caloric deficit — lipid profile shifts during a cut are the primary metabolic story to track, with Fragment's contribution captured in the body composition outcome rather than in lipid changes per se.
Post-cycle lipid re-check at 8-12 weeks captures cumulative cutting-phase metabolic improvement. Useful for users tracking the broader cutting-protocol outcome rather than Fragment-specific effects, since the article frames Fragment as one component of a multi-compound cutting protocol.
The article's practicalConsiderations explicitly directs tracking 'body composition changes (scale weight, waist circumference, visual assessment, caliper or DEXA if available)' as the primary outcome measure — given the absence of any blood biomarker to confirm Fragment use or quality. This is the article's own first-line tracking modality.
Post-cycle body composition re-check is the primary efficacy outcome per the article's framing. Fragment's mechanism produces fat loss in a specific protocol context (fasted, pre-exercise, deficit) — the post-cycle measurement is what determines whether the protocol delivered the intended outcome.
Avoid With
Do not combine Fragment 176-191 with the following. Sorted highest-severity first.
Why:Full-length GH contains residues 176–191 as part of its sequence — the fragment domain is already present in every IU of GH you inject. Adding standalone Fragment on top of full GH provides zero additive lipolytic signaling; the receptor interaction responsible for Fragment's effect is already fully covered by the GH molecule.
What to do:The most common Fragment-related waste of money in community practice. Users on 1+ IU/day pharmaceutical GH get no benefit from adding Fragment. Fragment is for users NOT running full GH — either on secretagogues only, or using no GH-axis compounds at all.
Why:Starting Fragment and sermorelin in the same week makes it impossible to attribute early adaptation effects to either compound. Sermorelin is often chosen specifically for sleep improvement; paradoxical sleep worsening, morning headaches, and nausea have been reported when both are started simultaneously.
What to do:Not a permanent safety concern — reported effects appear to be adaptation-phase phenomena. Standard fix: start one compound at a time. Start sermorelin first (given its sleep rationale), establish baseline response over 1–2 weeks, then add Fragment. If sleep disruption occurs after Fragment is added, the attribution is cleaner.
Why:In users under ~35–40 with strong baseline GH secretory capacity, secretagogue-driven GH pulses may already saturate the lipolytic pathway endogenously, leaving little room for Fragment to add incremental lipolysis. The compound's marginal value decreases as natural GH secretion increases.
What to do:This is an efficacy concern, not a safety concern. Older users (declining GH secretory capacity) get more additive value from Fragment on top of secretagogues than younger users do. Not a reason to avoid the combination — just a calibration for realistic outcome expectations in younger users.
Protocols By Goal
Fat loss / cutting. Reported practice centers on fasted, pre-activity use during a caloric deficit. Positive reports usually include fasted cardio or training and a willingness to judge results over a full cutting block rather than after a few injections.
Cost-constrained cutting. Some users reserve Fragment for training or cardio days, reasoning that the exercise-dependent mechanism makes rest-day use lower value.
TRT / HRT users seeking targeted fat-loss support. Fragment is discussed as a relatively clean add-on because it does not intentionally raise IGF-1 or disturb aromatase-management routines, but body-composition tracking still matters more than subjective feel.
GH secretagogue stack. Some users layer Fragment onto ipamorelin/CJC-style protocols for a separate lipolytic signal, while treating full exogenous GH as largely redundant with Fragment's intended domain.
Not appropriate for. Bulking phases, caloric surplus, protocols without fasted activity, tested sport, or users expecting a standalone fat-loss drug.
Dosing Details
Reported Fragment 176-191 use is highly protocol-dependent. Community practice usually describes 250-500 mcg subcutaneous exposure once or twice daily in a fasted state, with timing clustered around fasted cardio or training.
The logic is mechanism-based: post-meal insulin blunts lipolysis, so users who report benefit usually pair the peptide with low-insulin activity and a caloric deficit.
Some experienced users condense use to workout or cardio days only, treating rest-day dosing as lower value because the compound is being used as a lipolytic amplifier rather than a standalone fat-loss drug. Reported runs are usually cutting-phase windows measured in weeks. These are observed conventions, not validated clinical protocols.
The article deliberately does not provide reconstitution math or injection instructions. The practical takeaway is narrower: Fragment appears most coherent when the user is already creating the conditions for fat mobilization; it is a poor fit for bulking, post-meal use, or expectations of GLP-1-like fat loss without diet and activity structure.
Stacks & Alternatives
The most documented Fragment combination. Fragment handles direct lipolysis; ipamorelin/CJC-1295 drive pulsatile GH release for recovery, sleep quality, and lean mass preservation. The two mechanisms operate independently — Fragment's lipolytic pathway does not interact with the GHS-R1a receptor that ipamorelin targets. Standard advanced cutting protocol: Fragment 250 mcg AM fasted + ipamorelin 200–300 mcg + CJC-1295 DAC 2 mg/week.
GLP-1 receptor agonists and Fragment target complementary mechanisms. GLP-1 agonists reduce caloric intake, improve insulin sensitivity, and create a favorable metabolic state for fat loss; Fragment adds direct lipolytic signaling during fasted exercise windows. Both compounds work best in a caloric deficit. Community practitioners recommend this combination for aggressive cutting cycles, particularly when the user is willing to structure fasted training around the Fragment injection.
Community-theorized synergy based on mechanism: Fragment mobilizes free fatty acids out of adipose tissue into circulation; high-dose IGF-1 promotes cellular hyperplasia in skeletal muscle, which requires fatty acids as structural components of new cell membranes. The proposed effect is that mobilized fatty acids from Fragment are drawn into dividing muscle cells rather than re-esterized. This is mechanistically plausible but not directly tested — it remains a community hypothesis supported by experienced practitioners who have run both.
Alternatives
Stack Cost
Low systemic stack tax when used alone, but its practical burden rises quickly if the user cannot maintain fasted timing, injection logistics, and source-quality discipline.
The article makes the injection, fasted state, exercise window, and three-hour post-injection fast part of the mechanism rather than optional optimization.
At 500 mcg/day a 2 mg vial lasts about four days, and the article notes there is no blood marker that verifies product authenticity from RUO channels.
The main reported adverse effects are daytime lethargy and brain fog, with sleep disruption, headaches, and nausea mainly reported when Fragment was started simultaneously with sermorelin.
The article repeatedly frames the clinical safety profile as clean on IGF-1, glucose, insulin resistance, water retention, and carpal tunnel signals across the AOD-9604 trial program.
- ·Do not count Fragment as a substitute for diet structure; it only adds value inside a caloric deficit with fasted exercise.
- ·Avoid adding Fragment to full exogenous GH, since the article treats that combination as mechanistically redundant and financially wasteful.
- ·Stagger Fragment from sermorelin or other GH-axis additions by 1-2 weeks so fatigue, sleep disruption, headache, or nausea can be attributed.
- ·Requires injection logistics, storage discipline, and careful exposure tracking.
- ·Creates a need for body-composition tracking because standard bloodwork cannot confirm use or product quality.
- ·Benefits from baseline and midcycle sanity checks for IGF-1 and glucose when the user wants to verify the expected null GH-axis profile.
The article labels experience level as beginner and describes a clean clinical safety profile, but the protocol is easy to waste if timing, fasting, exercise, and sourcing are sloppy.
- ·User is already running full exogenous GH
- ·User cannot maintain fasted pre-exercise timing
- ·User needs a compound with directly verifiable bloodwork response
The article describes no receptor desensitization, no HPG suppression, and no GH-axis shutdown, so stopping mainly removes the short active lipolytic window.
- ·Loss of the fasted-exercise lipolysis amplifier
- ·Unclear attribution if stopped during a broader cutting protocol
Treat fasted pre-activity timing and caloric deficit as mandatory parts of the mechanism, not optional optimizations.
Do not add Fragment when full-length GH is already covering residues 176-191; choose either GH or a non-redundant fat-loss adjunct.
Start one compound at a time, pause or reduce the newest addition if symptoms are disruptive, and avoid simultaneous starts with sermorelin.
The article states Fragment/AOD-9604 are WADA-prohibited GH variants.
The article does not provide pregnancy or lactation safety data for this RUO peptide, and there is no clinical use case that justifies exposure.
The article treats this as redundant because full GH already includes the 176-191 domain.
The article says the protocol conditions are the mechanism; without them, Fragment is likely an injection with no active amplification context.
Practical Setup
The most important practical consideration is that protocol conditions are not minor optimizations; they are the mechanism.
Fragment is used to amplify fat mobilization when insulin is low and activity is occurring. Without a caloric deficit and fasted activity, users should expect weak or absent results.
No routine blood marker confirms Fragment exposure or product quality. It does not reliably raise IGF-1 or produce a simple verification signal. Outcome tracking therefore relies on body composition markers such as scale trend, waist measurement, photos, calipers, or DEXA when available.
Drug-tested athletes should avoid it because GH-fragment compounds are anti-doping sensitive. Users already running full exogenous GH generally treat Fragment as redundant. Avoid starting it simultaneously with other new compounds if attribution of lethargy, headaches, nausea, or sleep disruption matters.
Mechanism Deep Dive
Structure and GH domain separation Fragment 176-191 is a 16-amino acid synthetic peptide (C₇₈H₁₂₃N₂₃O₂₃S₂, MW ~1815.1 Da, CAS 221231-10-3) corresponding to residues 176–191 of the full 191-amino acid growth hormone sequence.
The sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe contains two cysteine residues that form a disulfide bridge, stabilizing the structure.
Growth hormone's biological activity is domain-dependent. A 1995 in vitro binding study established the functional division: the N-terminal domain (residues 1–43) carries somatogenic and anabolic activity, binding the GH receptor (GHR) and driving downstream IGF-1 production. The C-terminal region has fundamentally different receptor-binding characteristics — Fragment 176-191 operates at the C-terminal end, entirely outside the GHR-binding domain. This structural fact is the mechanistic basis for everything Fragment does and doesn't do: no GHR binding, no IGF-1 stimulation, no anabolic signaling. The lipolytic activity is a property of the C-terminal domain specifically.
Lipolytic mechanism Fragment 176-191 activates fat mobilization through a pathway distinct from GH receptor signaling, likely involving adipose β-adrenergic receptor interactions that trigger triglyceride breakdown (lipolysis) and free fatty acid release. The compound is not simply a partial agonist of GHR — it acts through an independent pathway that happens to produce one component of GH's downstream effects.
The half-life is approximately 30 minutes. This is mechanistically significant: the active lipolytic window is narrow, concentrated around the injection event. The protocol requirement of fasted pre-exercise injection is not arbitrary timing optimization — it positions the Fragment's peak activity window directly inside the period when insulin is lowest (fasted state) and metabolic demand is highest (exercise). Both conditions amplify the lipolytic signaling that Fragment initiates.
Insulin directly antagonizes lipolysis by activating phosphodiesterase, which degrades cAMP — the second messenger in the β-adrenergic lipolytic cascade. Even a moderate postprandial insulin rise suppresses lipolysis and blocks Fragment's mechanism at the cellular level. This is why the fasted requirement is mechanistic rather than clinical convention.
AOD-9604: Stabilized derivative AOD-9604 (Anti-Obesity Drug 9604) is Tyr-hGH177-191 — the native fragment with a tyrosine residue added to the N-terminus. This modification was made for the pharmaceutical development program, improving metabolic stability and potentially oral bioavailability. The community treats Fragment 176-191 and AOD-9604 as interchangeable, and experienced practitioners who have run both report no consistent practical difference in fat loss outcomes. Whether the structural modification produces pharmacokinetically meaningful differences at community doses has not been formally studied.
GH fragment selectivity Multiple GH fragments have been investigated for anti-obesity activity. Fragments 1–43 and 32–46 promote glucose homeostasis in animal models but did not demonstrate meaningful fat loss activity. Fragment 176-191 and AOD-9604 are the only GH fragments with documented lipolytic activity that extends to practical human community use — confirming that the lipolytic function maps specifically to the C-terminal domain and not to GH's other regions.
IGF-1 independence confirmed in six clinical trials The AOD-9604 drug development program (summarized by Stier, Vos, and Kenley in a 2013 Journal of Endocrinology and Metabolism paper covering all six randomized trials) confirmed that the compound does not significantly raise IGF-1 and does not cause insulin resistance or glucose impairment. These null results validate the structural prediction: the compound lacks the N-terminal domain required for GHR binding and IGF-1 stimulation. The six-trial safety confirmation is the most robust data point on this compound — it is consistently clean on the specific endpoints that matter for distinguishing Fragment from full GH.
No somatostatin feedback GHRP peptides (hexarelin, GHRP-6) stimulate the ghrelin receptor (GHS-R1a), triggering GH release but also inducing somatostatin counter-regulation that suppresses subsequent GH pulses. Fragment 176-191 does not activate GHS-R1a and therefore does not trigger this somatostatin feedback loop. It can be added to GHRP and GHRH protocols without blunting the pulsatile GH release that those compounds drive.
Proposed IGF-1 / fat mobilization synergy A mechanistically proposed (not clinically tested) synergy between Fragment and high-dose IGF-1 DES or LR3: Fragment drives free fatty acid release from adipose tissue into circulation; IGF-1 at high doses promotes cellular hyperplasia in skeletal muscle. Because cell membrane biosynthesis requires fatty acids as structural components, the theory is that new cell division driven by IGF-1 draws on the circulating fatty acids that Fragment mobilized, reducing their re-esterification back into adipose tissue. Community practitioners who run both report this as potent during hard cuts. The synergy is mechanistically plausible but constitutes community-level hypothesis rather than confirmed pharmacology.
Drug development failure context The Phase 2b/3 clinical trial failure for obesity treatment (efficacy failure, not safety) occurred in a specific context: obese patients, monotherapy, no structured exercise protocol. The failure does not imply the compound is pharmacologically inactive — early Phase 1/2 studies showed positive fat metabolism activity sufficient to justify a drug program, and animal models showed consistent body weight reduction across species. The failure means the effect size was insufficient to displace other obesity treatments in a clinical trial population. Community practitioners use Fragment as one component of multi-compound cutting protocols with caloric restriction and structured exercise — a context not evaluated in the obesity drug trials.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
The AOD-9604 clinical program is described as six randomized trials with no significant IGF-1 elevation, insulin resistance, glucose impairment, mutagenic activity, or serious adverse-event signal.
Use this claim as safety scoping for AOD-9604/Fragment-like exposure, not proof of strong fat-loss efficacy in trained cutting protocols.
Phase 2b/3 obesity trials failed to show clinically meaningful weight loss as monotherapy.
The article explicitly separates this failed clinical context from community use during caloric restriction and fasted exercise.
Animal models including Zucker rats, mice, and rabbits showed consistent body-weight reduction.
Supports biological plausibility only; do not translate the magnitude directly to human cutting outcomes.
Community reports cluster around 250-500 mcg fasted pre-cardio dosing, often one to two times daily during an 8-12 week cutting phase.
Reports are highly confounded by diet, training, and simultaneous compounds; treat as protocol texture, not isolated efficacy proof.
The article describes an approximately 30-minute half-life and builds the dosing protocol around a short fasted exercise window.
This scopes the timing logic; it does not prove that any specific body-composition outcome follows from the timing protocol.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.